Labopharm to be acquired by Paladin Labs

Labopharm (NASDAQ:DDSS; TSX:DDS) has accepted a takeover bid from Paladin Labs (TSX:PLB), which will make an offer for all of the common shares of Labopharm at a price of 28.57 cents a share in cash. The purchase price represents a premium of 57.4% over the volume-weighted average price of Labopharm’s shares of 18.15 cents for the 30 trading [...]

Paladin eyes Mexico and Brazil for expansion

Pharmaceutical distributor Paladin Labs (TSX:PLB) has set its sights on moving into Mexico and Brazil as it continues its strategy of expanding internationally to complement its growth in Canada. “I would like to be in more geographies, and we’re keenly interested in Mexico and Brazil and looking to do something there,” CEO Jonathan Goodman says [...]

Cormark upgrades Paladin to top pick

Cormark Securities has upgraded Paladin Labs (TSX:PLB) to “top pick” with a new price target of $30 from “buy” and $24.50 on the back of another strong quarter that beat its estimates for revenue, EBITDA and earnings.  The stock closed at $25.45 on Thursday. Analyst David Dean writes that the company’s first quarter performance is [...]

Paladin in strategic relationship with Dutch specialty pharma

Stepping beyond its Canadian market, Paladin Labs (TSX:PLB) is investing four million Euros through a secured convertible debenture in SpePharm Holding BV, a Dutch specialty pharma company, in a new relationship that “establishes significant future strategic collaboration and value potential for both parties.” Under the accord, Paladin can convert the debenture into an approximate 10% [...]

Paladin in distribution pact with BTG

Paladin Labs (TSX:PLB) has entered into a distribution agreement with Protherics, a unit of BTG PLC, for the exclusive Canadian rights to market and sell DigiFab, which is under Health Canada review to treat life-threatening or potentially life-threatening digoxin toxicity or overdose. “DigiFab provides an important opportunity to grow Paladin’s specialty and orphan franchise, which [...]

Isotechnika amends deal with Paladin Labs

Isotechnika Pharma’s (TSX: ISA) wholly owned subsidiary, Isotechnika Labs, has amended its agreement with Paladin Labs (TSX:PLB) on the remaining stake in the revenue stream from the Isodiagnostika business, which was sold to Paladin in mid-2009. Under the original deal, Isotechnika Labs was entitled to receive a revenue stream equivalent to 88% of the net [...]

Cash-rich Paladin on the acquisition trail

Paladin Labs (TSX:PLB) is sitting on a war chest of some $97 million that’s growing by the quarter and itching to be deployed. “We’re going to invest in opportunities with a high return on investment,” CEO Jonathan Goodman, says in an exclusive interview with biotuesdays.com.  “But I’m not going to bet the company on a [...]

Paladin results beat consensus

RBC Capital Markets has revised upwards its financial model for Paladin Labs (TSX:PLB) after the company posted third quarter results on Wednesday that were slightly higher than consensus. Analyst Doug Miehm writes that Paladin’s results support “our positive investment thesis.  What we continue to find compelling about the story is the company’s unique strategy, with [...]

RBC starts Paladin at “outperform”

RBC Capital Markets has initiated coverage of Paladin Labs (TSX: PLB) with an “outperform” rating and 12-month price target of $23.  The stock finished trading at $18 on Friday. “What we find compelling about the story is the company’s unique strategy with a particular focus on free cash flow generation and growth in a conservative [...]

There’s no let up at Paladin Labs

The fast growing specialty pharma is guiding to revenues of more than $100-million this year, compared with $82.7-million in 2008, CEO Jonathan Goodman, said  in notes for a presentation at BioContact in Quebec City.  He cited strong organic growth from new product launches including, Anacin/Anbesol, Dexedrine and Urocit-K. Paladin, which focuses on acquiring or in-licensing [...]